Oral ATP (Adenosine Triphosphate) trials recruiting now
2 registrations that name oral ATP as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
All 2 registrations
RecruitingNCT07085975
The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges
Phase 1
McMaster University
About 33 people
Started Aug 5, 2025
In plain words A Phase 1 study of oral ATP in people 18 and older, run by McMaster University. It plans to enroll about 33 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Chronic Cough (CC); Asthma.
Normal spirometry; and
No current or past medical history of chronic cough or other respiratory diseases.
The exclusion criteria are on the listing.
What it tests, as registered
Adenosine 5'-triphosphate
Registered summary
The inhalation of adenosine 5'-triphosphate (ATP) to evoke cough (ATP cough challenge) is becoming increasingly used as a tool to measure cough hypersensitivity in patients with chronic cough. However, the safety, feasibility, and repeatability of this procedure is not widely known. In this study, we will perform ATP cough challenges in healthy individuals and in patients with mild asthma and chronic cough to better understand the safety, feasibility, and repeatability of these challenges. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
Not yet recruitingNCT07296354
Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy
Phase 4
Egyptian International Pharmaceutical Industries Co
About 200 people
Starts Jan 10, 2026 (estimated)
In plain words A Phase 4 study of oral ATP in people 18 to 70, run by Egyptian International Pharmaceutical Industries Co. It plans to enroll about 200 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70; healthy volunteers accepted. Conditions: Neuropathic Pain.
Patients ≥ 18 years of age at time of consent
Able to provide informed consent for study participation.
Diagnosed with either Type 1 or Type 2 diabetes mellitus, with glycated hemoglobin (HbA1c) ≤ 10%
Diagnosed with diabetic polyneuropathy, defined as a Diabetic Neuropathy Symptom (DNS) score ≥ 2, with symptom duration of at least 3 months prior to providing informed consent.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
adenosine triphosphate; Vitamin B Complex
Registered summary
Epinosine B Forte ampoule is an intramuscular injectable supplement containing adenosine triphosphate (ATP), Cocarboxylase (vitamin B1 derivative), vitamin B12, and nicotinamide (vitamin B3). It is used to support nerve function, treat B vitamin deficiencies, enhance cellular energy metabolism, and alleviate symptoms of fatigue, neuropathy, and general weakness. Commonly prescribed for conditions like peripheral neuritis and recovery from nerve-related disorders. Side effects are generally mild and may include local injection site reactions or allergic responses. The full summary is on the listing.